Savara, Inc. (SVRA): Price and Financial Metrics


Savara, Inc. (SVRA): $1.58

-0.06 (-3.66%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SVRA Stock Price Chart Interactive Chart >

Price chart for SVRA

SVRA Price/Volume Stats

Current price $1.58 52-week high $1.91
Prev. close $1.64 52-week low $1.02
Day low $1.51 Volume 98,700
Day high $1.66 Avg. volume 139,655
50-day MA $1.31 Dividend yield N/A
200-day MA $1.38 Market Cap 180.19M

Savara, Inc. (SVRA) Company Bio


Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is based in Austin, Texas.


SVRA Latest News Stream


Event/Time News Detail
Loading, please wait...

SVRA Latest Social Stream


Loading social stream, please wait...

View Full SVRA Social Stream

Latest SVRA News From Around the Web

Below are the latest news stories about SAVARA INC that investors may wish to consider to help them evaluate SVRA as an investment opportunity.

Savara Announces New Employment Inducement Grant

AUSTIN, Texas, November 22, 2022--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of an employee inducement award.

Yahoo | November 22, 2022

H.C. Wainwright Reaffirms Their Buy Rating on Savara (SVRA)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Savara (SVRA - Research Report), with a price target of $3.00. The company's shares closed last Friday at $1.17.Fein covers the Healthcare sector, focusing on stocks such as Unity Biotechnology, Wave Life Sciences, and ACADIA Pharmaceuticals. According to TipRanks, Fein has an average return of -10.6% and a 35.48% success rate on recommended stocks. Currently, the analyst consensus on Savara is a Moderate Buy with an average price target of $3.00.

Christine Brown on TipRanks | November 14, 2022

Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

AUSTIN, Texas, November 10, 2022--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2022 and provided a business update.

Yahoo | November 10, 2022

Savara to Participate in Three Upcoming Investor Conferences

AUSTIN, Texas, November 09, 2022--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate at the following investor healthcare conferences:

Yahoo | November 9, 2022

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

AUSTIN, Texas, September 14, 2022--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees.

Yahoo | September 14, 2022

Read More 'SVRA' Stories Here

SVRA Price Returns

1-mo 33.90%
3-mo 8.97%
6-mo 17.04%
1-year 46.30%
3-year 18.80%
5-year -88.29%
YTD 27.42%
2021 7.83%
2020 -74.33%
2019 -40.82%
2018 -48.99%
2017 135.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7869 seconds.